SLN
Silence Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$19.58
+125.58%Oct 19, 2026, 13:40 UTC
Halper Sadeh LLC said it is investigating whether Silence Therapeutics plc and its board obtained a fair price in the company's sale to Merck & Co., Inc. for $20.00 in cash per American Depositary Share.
Source:Oct 19, 2026, 12:56 UTC
Silence Therapeutics plc shares doubled in premarket trading to $19.62.
Source:Oct 19, 2026, 12:12 UTC
Certain Silence Therapeutics securityholders holding approximately 14% of its voting power agreed to support the proposed transaction and restrict dispositions of their securities, subject to the agreement's terms.
Oct 19, 2026, 12:01 UTC
Merck KGaA will acquire Silence Therapeutics plc.
Aug 10, 2026, 20:01 UTC
Silence Therapeutics announced the commencement of an underwritten public offering of approximately $150 million of its American Depositary Shares in the United States.
Aug 10, 2026, 11:31 UTC
Silence Therapeutics announced Phase 2 trial results for its experimental drug divesiran in polycythemia vera, showing 88% clinical response rate versus 19% for placebo, positioning it to compete with Takeda's near-approval drug.
Aug 10, 2026, 00:00 UTC
Silence Therapeutics plc reported its Q2 2026 financial results, with zero revenue, a net loss of $12.3 million, and diluted loss per share of $0.09, compared to a net loss of $27.4 million in Q2 2025.
Jun 12, 2026, 14:47 UTC
Silence Therapeutics Plc highlighted follow-up data from its Phase 1 SANRECO study of divesiran.
Source: